Revolution Medicines’ stock has surged on the promise of a pancreatic-cancer drug. With any deal to buy the firm looking unlikely, investors should be prepared for the long haul.
About the Author
Discover more from InfoVera USA
Subscribe to get the latest posts sent to your email.
